These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6803307)

  • 1. Increased platelet activity after termination of prostacyclin infusion into man.
    Dembinska-Kiec A; Zmuda A; Grodzinska L; Bieron K; Basista M; Kedzior A; Kostka-Trabka E; Telesz E; Zelazny T
    Prostaglandins; 1981 May; 21(5):827-32. PubMed ID: 6803307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Platelet thromboxane A2 and arterial prostacyclin by dietary vitamin E.
    Karpen CW; Merola AJ; Trewyn RW; Cornwell DG; Panganamala RV
    Prostaglandins; 1981 Oct; 22(4):651-61. PubMed ID: 6798639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dipyridamole on prostaglandin generation by human platelets and vessel walls.
    Mehta J; Mehta P; Hay D
    Prostaglandins; 1982 Dec; 24(6):751-61. PubMed ID: 6820166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of heparin on platelet aggregation and release and thromboxane A2 production.
    Mohammad SF; Anderson WH; Smith JB; Chuang HY; Mason RG
    Am J Pathol; 1981 Aug; 104(2):132-41. PubMed ID: 7258300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
    Reele SB; Miller OV; Spillers C; Gorman RR
    Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in-vitro.
    Greer IA; Walker JJ; McLaren M; Calder AA; Forbes CD
    Thromb Res; 1986 Feb; 41(4):509-18. PubMed ID: 3083526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The modification of the biosynthesis and effect of thromboxane A2 and prostacyclin by trapidil (Rocornal)].
    Block HU; Heinroth I; Giessler C; Pönicke K; Mentz P; Zehl U; Rettkowski W; Dunemann A; Förster W
    Biomed Biochim Acta; 1983; 42(2-3):283-99. PubMed ID: 6411078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of platelet responses to metabolites of arachidonic acid by oral contraceptives.
    Pan IQ; Hall ER; Wu KK
    Br J Haematol; 1984 Oct; 58(2):317-23. PubMed ID: 6089860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N
    Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans.
    Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T
    Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655
    [No Abstract]   [Full Text] [Related]  

  • 13. Some properties of mouse platelets.
    Rosenblum WI; Nelson GH; Cockrell CS; Ellis EF
    Thromb Res; 1983 May; 30(4):347-55. PubMed ID: 6412387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggregation and thromboxane B2 formation in platelets and vascular prostacyclin production from genetically obese rats.
    Landgraf-Leurs MM; Loy A; Christea C; Weber PC; Siess W; Herberg LL; Landgraf R
    Prostaglandins; 1981 Oct; 22(4):521-36. PubMed ID: 6798637
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of prostacyclin in the separation from plasma and washing of human platelets.
    Vargas JR; Radomski M; Moncada S
    Prostaglandins; 1982 Jun; 23(6):929-45. PubMed ID: 6812168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
    Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
    Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregation and thromboxane formation by platelets and vascular prostacyclin production from BB rats. An animal model for type I diabetes.
    Landgraf-Leurs MM; Landgraf R; Loy A; Weber PC; Herberg LL
    Prostaglandins; 1982 Jul; 24(1):35-46. PubMed ID: 6812171
    [No Abstract]   [Full Text] [Related]  

  • 18. Ethanol inhibits platelet thromboxane A2 production but has no effect on lung prostacyclin synthesis in humans.
    Toivanen J; Ylikorkala O; Viinikka L
    Thromb Res; 1984 Jan; 33(1):1-8. PubMed ID: 6364450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental atherosclerosis in rabbits: platelet aggregation, thromboxane A2 generation and anti-aggregatory potency of prostacyclin.
    Zmuda A; Dembinska-Kiec A; Chytkowski A; Gryglewski RJ
    Prostaglandins; 1977; 14(6):1035-42. PubMed ID: 341225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.